Enthesitis Responses to Secukinumab in Spondylitis Patients Save

Schett and colleagues studies the secukinumab (an IL-17 inhibitor) response in patients from 3 clinical trials with enthesitis and ankylosing spondylitis (AS) and demonstrated consistent efficacy with improved enthesitis scores at both peripheral and axial sites.

Pooled data from the MEASURE 1-4  clinical trials examined enthesopathy outcomes using the Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) in these 52 week studies.

Overall, 693 (71.5%) of enrolled patients had enthesitis at baseline and were then randomized to receive secukinumab (SEC) 300 mg, 150 mg or placebo groups.

At Week 16 (the primary analysis point), the mean change in overall enthesitis and axial enthesitis (by MASES) was:

• SEC 300 mg: -2.9 [P<0.01] and -2.9 [P<0.01 vs PBO] 
• SEC 150 mg; -2.4 [P<0.015] and -2.3 [P<0.05 vs PBO]
• Placebo: -1.9 and -1.8

These same improvements were seen through Week 52 and 36% (300 mg) to  418% (150 mg) hd complete resolution of enthesitis by Week 16.